General MedicationsINJECTIONStandard
POTELIGEO
MOGAMULIZUMAB-KPKC
Standard Dose
20MG/5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview POTELIGEO is listed in Drugs@FDA under application 761051 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient MOGAMULIZUMAB-KPKC Form and strength INJECTABLE;INJECTION - 20MG/5ML Sponsor KYOWA KIRIN Submission history Latest submission status date: 2026-02-19 00:00:00.
Structured Monograph
Clinical summary
Approval overview POTELIGEO is listed in Drugs@FDA under application 761051 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient MOGAMULIZUMAB-KPKC Form and strength INJECTABLE;INJECTION - 20MG/5ML Sponsor KYOWA KIRIN Submission history Latest submission status date: 2026-02-19 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.